Conference: 2026 ISPE Annual Meeting
Date: August 29 - September 2, 2026
Location: Milan, Italy
Booth: 406
Linking data to solve common yet complex challenges in studying rare disease
Certara’s experts help you overcome:
- Limited data caused by inherently small patient populations
- Fragmented, hard-to-find patients dispersed patient populations
- Incomplete data sources that capture some outcomes and resource utilization but lack granular clinical measures or quality of life data
Join our poster presentations and spotlight posters on rare disease
12:00PM – 1:30PM CEST
Presenting Author: Stephanie H Read, PhD
Using the EMA Data Quality Framework, this study illustrates a structured, reproducible approach to assessing the fitness-for-use of three real-world data sources for regulatory-grade CAR-T cell therapy research.
11:30AM – 1:00PM CEST
Presenting Author: Stephanie H Read, PhD
This post-authorization drug utilization study leverages nationwide French claims data (SNDS) to characterize real-world tofacitinib prescriber adherence to dosing, screening, and monitoring recommendations, supporting ongoing evaluation of this Janus kinase inhibitor’s risk minimization measures.
12:00PM – 1:30PM CEST
Presenting Author: Alekhya Lavu, PhD, PharmD
The study evaluates the healthcare resource utilization and economic burden of EoE using real-world EMR and claims data. It highlights substantial healthcare utilization and costs among patients with documented and potential undiagnosed EoE, underscoring the burden of EoE and potential gaps in diagnosis.
12:15 PM – 1:15 PM CEST
Presenting Author: Giancarlo Pesce, PhD
This work triangulates three independent US real-world data sources — the CureGN Registry, the TriNetX EHR network, and a single-center chart review — to characterize IgAN disease course, treatment patterns, and clinical outcomes before and after FDA approval of delayed-release budesonide (Nefecon). Together, the three sources capture complementary views of the same disease — long-term natural history, comparative safety and cost, and early post-approval outcomes — that no single data source could provide.
12:15PM – 1:15PM CEST
Presenting Author: Alekhya Lavu, PhD, PharmD
This study characterizes the burden of type 2 inflammatory conditions and other EoE specific comorbidities among patients with documented and potential EoE using real-world US data.
12:15PM – 1:15 PM CEST
Presenting Author: Stephanie H Read, PhD
This study establishes a novel data linkage between the DM-Scope registry and the French SNDS claims database to develop and validate the first predictive algorithm for distinguishing between Myotonic Dystrophy Type 1 and Type 2 patients in administrative healthcare data.
You May Also Like
From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence.
